 |
Analyze a Pharmaceutical Company: Corporate Strategy, Statements, Drugs in the Pipeline, Product Portfolios and Financial Data?
TOPIC: IMS Company Profiles (File 449, 984) examines annually the internal make-up of nearly 100 key pharmaceutical companies worldwide. Each individual profile analyzes the critical components that affect a company's business strategy, giving a clear assessment of a company's relative strengths and weaknesses. Companies profiled include public and private, producing ethical, biotech, or generic pharmaceuticals. File 449 is publicly available; File 984 is available only to subscribers of electronic or equivalent products from IMS. The record structure is identical between the two files.
In this example you will research Pfizer and TYPE out a record of its R&D pipeline.
COMMAND SUMMARY
BEGIN 449
EXPAND CO=PFIZER
SELECT E3
RANK SE CONT ALL
Follow the Rank menu
EXS
SELECT S1 AND S20 AND PY=2008
TYPE S21/6/ALL
TYPE S21/9/12
HOW TO...
1. BEGIN File 449 to search IMS Company Profiles for a company.
2. EXPAND the company name using the Company Name (CO=) field. Use standard punctuation, spacing and word order.
3. SELECT the appropriate “E” Reference number. |
?b 449
File 449:IMS COMPANY PROFILES 2008/MAY
(c) 2008 IMS HEALTH & AFFILIATES
Set Items Description
--- ----- -----------
?e co=pfizer
Ref File Items Total Index-term
E1 449 54 CO=OTSUKA
E2 449 40 CO=PAR PHARMACEUTICALS
E3 449 60 *CO=PFIZER
E4 449 46 CO=PIERRE FABRE
E5 449 44 CO=PROCTER & GAMBLE
E6 449 49 CO=RANBAXY
E7 449 35 CO=RATIOPHARM
E8 449 49 CO=RECORDATI
E9 449 56 CO=ROCHE
E10 449 60 CO=SANOFI-AVENTIS
E11 449 55 CO=SCHERING-PLOUGH
E12 449 30 CO=SEPRACOR
E13 449 42 CO=SERVIER
. . . .
Enter P or PAGE for more
?s e3
S1 60 CO='PFIZER' |
4. RANK the results of Set 1 on the Section Name field (SE).
5. Follow the Rank menu prompts.
Enter ALL to see a list of all of the sections in the retrieved records.
6. Enter a title for the RANKed list (optional).
Note: Part of this record is omitted from the display.
7. Identify Rank numbers to retrieve various section names. |
?rank se cont
Started processing RANK
Completed Ranking 60 records
Press ENTER to view the TOP 50 terms
or enter a number N to view the top N terms
or >N to view terms with more than N items
or enter ALL to view all terms
?all
Enter title for continuous output or press ENTER
for current title option
?pfizer company profile
Adding title to results...
PFIZER COMPANY PROFILE
----------------------
RANK: S1/1-60 Field: SE= File(s): 449
(Rank fields found in 60 records -- 57 unique terms)
RANK No. Items Term
-------- ----- ----
1 2 CORPORATE STRUCTURE
2 2 FINANCIAL DATA TABLE : IMS SALES DATA BY PRODU
3 2 FINANCIAL DATA TABLE : KEY FIGURES
4 1 FINANCIAL DATA TABLE : ANALYSTS FORECASTS
5 1 FINANCIAL DATA TABLE : BUSINESS SECTORS
6 1 FINANCIAL DATA TABLE : GEOGRAPHICAL REGIONS
7 1 FINANCIAL DATA TABLE : IMS SALES DATA BY COUNT
8 1 FINANCIAL DATA TABLE : IMS SALES DATA BY SUBSI
9 1 FINANCIAL DATA TABLE : IMS SALES DATA BY TOP 5
10 1 FINANCIAL DATA TABLE : THERAPEUTIC CATEGORIES
11 1 FINANCIAL REVIEW
12 1 FINANCIAL REVIEW : ANALYST COMMENT
13 1 LICENSING & CO-MARKETING AGREEMENTS TABLE : GE
14 1 LICENSING & CO-MARKETING AGREEMENTS TABLE : MA
15 1 LICENSING & CO-MARKETING AGREEMENTS TABLE : R&
16 1 MAJOR EVENTS : MERGERS & ACQUISITIONS
17 1 MAJOR EVENTS : OTHER
18 1 PRODUCT PORTFOLIO : ALIMENTARY TRACT AND METAB
(…)
31 1 PRODUCT PORTFOLIO TABLE : PRODUCTS FACING PATE
32 1 R&D PIPELINE TABLE
33 1 R&D PROFILE : ALIMENTARY TRACT AND METABOLISM
34 1 R&D PROFILE : ANTINEOPLASTICS/IMMUNOMODULATING
35 1 R&D PROFILE : BLOOD AND BLOOD-FORMING ORGAN AG
(…)
48 1 STRATEGY STATEMENT : BACKGROUND
49 1 STRATEGY STATEMENT : FUTURE PROSPECTS
50 1 STRATEGY STATEMENT : IMPACT OF FUTURE EVENTS
51 1 STRATEGY STATEMENT : INTRODUCTION
52 1 STRATEGY STATEMENT : LICENSING
53 1 STRATEGY STATEMENT : M&A ACTIVITY
54 1 STRATEGY STATEMENT : PATENT ISSUES
55 1 STRATEGY STATEMENT : R&D
56 1 STRATEGY STATEMENT : REGIONAL STRATEGY
57 1 STRATEGY STATEMENT : THERAPEUTIC FOCUS
---end of results---
P = next page Pn = Jump to page n
P- = previous page M = More Options Exit = Leave RANK
To view records from RANK, enter VIEW followed by RANK number,
format, and item(s) to display, e.g., VIEW 2/9/ALL.
Enter desired option(s) or enter RANK number(s) to save terms.
?1,3,7,8,9,10,16,32,48-57 |
Dialog confirms it has Saved the selected RANK terms.
The RANK menu reappears with its first eight numbers.
8. Enter EXIT to leave RANK.
9. Enter YES or Y to complete the exit from RANK. |
RANK numbers saved: 1,3,7-10,16,32,48-57
PFIZER COMPANY PROFILE
----------------------
RANK: S1/1-60 Field: SE= File(s): 449
(Rank fields found in 60 records -- 57 unique terms) Page 1
of 8
RANK No. Items Term
-------- ----- ----
1 2 CORPORATE STRUCTURE
2 2 FINANCIAL DATA TABLE : IMS SALES DATA BY PRODU
3 2 FINANCIAL DATA TABLE : KEY FIGURES
4 1 FINANCIAL DATA TABLE : ANALYSTS FORECASTS
5 1 FINANCIAL DATA TABLE : BUSINESS SECTORS
6 1 FINANCIAL DATA TABLE : GEOGRAPHICAL REGIONS
7 1 FINANCIAL DATA TABLE : IMS SALES DATA BY COUNT
8 1 FINANCIAL DATA TABLE : IMS SALES DATA BY SUBSI
P = next page Pn = Jump to page n
P- = previous page M = More Options Exit = Leave RANK
To view records from RANK, enter VIEW followed by RANK number,
format, and item(s) to display, e.g., VIEW 2/9/ALL.
Enter desired option(s) or enter RANK number(s) to save terms.
?exit
RANK results will be erased; have you saved all the terms
of interest? (YES/NO)
?y |
Dialog created a Temporary Save of the item numbers you entered and gave it a number (“TD027”).
10. EXECUTE STEPS (EXS) to run the SearchSave.
11. Combine the company name (S1) with S20, which contains the section names ORed together. This confines the focus to this company name of interest, since EXS searches for all section names in the database.
12. SELECT S1 and s20 and py=nnnn to restrict to a specific publication year (PY=). |
Temp SearchSave "TD027" stored
Creating temporary SearchSave ... TD027
Enter EXS to execute the SearchSave
?exs
Executing TD027
S2 178 SE="CORPORATE STRUCTURE"
S3 172 SE="FINANCIAL DATA TABLE : KEY FIGURES"
S4 81 SE="FINANCIAL DATA TABLE : IMS SALES DATA BY COUNT"
S5 81 SE="FINANCIAL DATA TABLE : IMS SALES DATA BY SUBSI"
S6 81 SE="FINANCIAL DATA TABLE : IMS SALES DATA BY TOP 5"
S7 18 SE="FINANCIAL DATA TABLE : THERAPEUTIC CATEGORIES"
S8 87 SE="MAJOR EVENTS : MERGERS & ACQUISITIONS"
S9 87 SE="R&D PIPELINE TABLE"
S10 58 SE="STRATEGY STATEMENT : BACKGROUND"
S11 89 SE="STRATEGY STATEMENT : FUTURE PROSPECTS"
S12 27 SE="STRATEGY STATEMENT : IMPACT OF FUTURE EVENTS"
S13 89 SE="STRATEGY STATEMENT : INTRODUCTION"
S14 66 SE="STRATEGY STATEMENT : LICENSING"
S15 73 SE="STRATEGY STATEMENT : M&A ACTIVITY"
S16 30 SE="STRATEGY STATEMENT : PATENT ISSUES"
S17 87 SE="STRATEGY STATEMENT : R&D"
S18 76 SE="STRATEGY STATEMENT : REGIONAL STRATEGY"
S19 87 SE="STRATEGY STATEMENT : THERAPEUTIC FOCUS"
S20 1523 S2:S20
?s s1 and s20 and py=2008
60 S1
1523 S21
1924 PY=2008
S21 21 S1 AND S21 AND PY=2008 |
13. TYPE the records in Format 6, which gives titles, publication date and word counts.
To select the appropriate record number, look at the numbers above each record, e.g. 21/6/2.
Note: Some records are omitted from the display. |
?t s21/6/all
DIALOG(R)File 449: IMS COMPANY PROFILES
(c) 2008 IMS HEALTH & AFFILIATES. All rights reserved.
00140214 (USE FORMAT 7 FOR FULLTEXT)
PFIZER: STRATEGY STATEMENT : INTRODUCTION
March 03 2008
Word Count: 1,089
21/6/2
DIALOG(R)File 449: IMS COMPANY PROFILES
(c) 2008 IMS HEALTH & AFFILIATES. All rights reserved.
00140213 (USE FORMAT 7 FOR FULLTEXT)
PFIZER: STRATEGY STATEMENT : BACKGROUND
March 03 2008
Word Count: 381
(….)
21/6/12
DIALOG(R)File 449: IMS COMPANY PROFILES
(c) 2008 IMS HEALTH & AFFILIATES. All rights reserved.
00140172 (USE FORMAT 7 FOR FULLTEXT)
PFIZER: R&D PIPELINE TABLE
March 03 2008
Word Count: 2,677
21/6/13
DIALOG(R)File 449: IMS COMPANY PROFILES
(c) 2008 IMS HEALTH & AFFILIATES. All rights reserved.
00140167 (USE FORMAT 7 FOR FULLTEXT)
PFIZER: FINANCIAL DATA TABLE : KEY FIGURES
March 03 2008
Word Count: 208 |
14. TYPE desired records in Format 9, the full record.
Note: Portions of the record are shown.
The code refers to the code letters used for experimental substances. An explanation of the code prefixes is given in a table in the printed copy of the Merck Index and is a mnemonic of the company name.
For example, apixaban’s code (BMS 562247) indicates the substance was developed by Bristol-Myers Squibb and is the 562247th compound that was given a code within the company.
The class (B2C) refers to the therapeutic class code used by IMS Health. B2C indicates the drug is a proteinase inhibitor.
The Phase refers to the FDA Drug Development Phase (Phase I, Phase II, Phase III, Filed as an Investigational New Drug Application (IND), Approved).
Chemical searching techniques can be used to elucidate more data in other files about the individual drugs that are produced by the company of interest. |
?t s21/9/12
21/9/12
DIALOG(R)File 449: IMS COMPANY PROFILES
(c) 2008 IMS HEALTH & AFFILIATES. All rights reserved.
00140172 (THIS IS THE FULLTEXT)
PFIZER: R&D PIPELINE TABLE
Main Title: PFIZER
Source: IMSworld Publications, Ltd Telephone: +44 20 3075 5000
March 03 2008
Language: English Record Type: Fulltext
Word Count: 2,677
Compound Code Class Phase
fesoterodine SPM 907 G4B4 Approved
lasofoxifene CP 336156 G3J Approved
dalbavancin MDL 63397 J1X Filed
anidulafungin, -- J2A III
voriconazole
anxiolytic PD 332334 N5C III
apixaban BMS 562247-01, B2C III
BMS 562247
axitinib AG 13736 L1X9 III
(…)
sexual health therapy PF 446687 G4B9 II
short stature/growth PH 794428 H4V II
therapy
signal transduction AG 13958 S1P II
inhibitor
skin therapy PF 275366 D11A II
tanezumab PF 4383119, RN N2B II
624
Type II diabetes therapy PF 734200 A10B9 II
ulcerative colitis PF 547659 A7E II
therapy
urinary tract therapy UK 369003 G4E II
vascular endothelial SU 14813 L1X9 II
growth factor receptor
inhibitor
VEGF receptor tyrosine CP 547632 L1X9 II
kinase inhibitor
-- PF 3392455 C2A I
-- PF 3463275 N5A I
(…)
alopecia therapy PF 277343 D11A I
Alzheimer's therapy PF 3084014 N7D9 I
angiogenesis inhibitor CVX 045 L1X9 I
(…)
VEGFR-2 inhibitor PF 337210 L1X9 I
-- CVX 096 A10X Preclinical
-- TS 032 N5A Preclinical
delta opioid receptor ADL 5747 N2A Preclinical
agonist
(….)
Copyright (c) 2008 IMSworld Publications, Ltd. All rights reserved.
Company: PFIZER |
RELATED HOW DO I...? SOLUTIONS
NEED HELP?
Contact the Dialog Knowledge Center
Within North America +1 800 3 DIALOG (334 2564)
Outside North America 00 800 33 DIALOG (33 34 2564)
Web Form www.dialog.com/contacts/webform
|
You are viewing the
Click below to view the
 |
